More programs, more candles, more light.





Get the Flash Player to see this player.


Loading the player ...

Panel 4: Robert Deans, Athersys, Inc.

Stem Cells in Clinical Trials

November 30, 2011
15 minutes
Robert Deans
 

 

Dr. Deans holds degrees from MIT and the University of Michigan, and conducted his postdoctoral training in molecular immunology at UCLA. He is responsible for regenerative medicine technology development at Athersys, Inc. and its European subsidiary, ReGenesys. Athersys is developing cell therapeutics based on adherent stem cells (MultiStem) isolated from adult bone marrow. Athersys has active Phase I and II clinical development activity in acute myocardial infarct, stroke, ulcerative colitis and for adjunctive therapy of allogeneic bone marrow transplant. Dr. Deans is also chairman of the International Society for Cellular Therapy (ISCT) Commercialization Committee and serves on a number of regulatory advisory committees. Dr. Deans has more than 20 years of experience in stem cell therapeutics, having previously served at Osiris Therapeutics as vice president of research. Dr. Deans was previously director of R&D at Baxter Healthcare, where he developed biological components of the Isolex300i hematopoietic stem cell purification platform. In addition, Dr. Deans served on the faculty at University of Southern California (USC) Medical School from 1984 to 1992.